In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Abaloparatide (Tymlos) | Natural peptide Thymosin beta-4 (human) | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Natural peptide | |
| Area | Recovery and repair | Recovery and repair | |
| Evidence | |||
| Amount of evidence | 878 | 1,449 (plus 953 on natural levels, listed separately) | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 84 (70 in people) | 12 (8 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 21 · 5 active4 more mention it but do not test it | 13 · 1 active2 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
The FDA label for Tymlos says: “A synthetic PTH-related peptide analog approved for osteoporosis in selected patients”
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Abaloparatide (Tymlos) | Thymosin beta-4 (human) |
|---|---|---|
| Bone and jointMusculoskeletal | 724290395354 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
Its most advanced trial is in phase 3. The FDA, the EMA and the other sources we use show no approval (as of 8 Oct 2026).
531142
| Receptor activity and mechanismReproductive and sexual health | 43241 | 310292792 |
|---|
| Adverse eventsWhole body | 43412 | 981 |
|---|
| Inflammation markersReproductive and sexual health | 211 | 1447668 |
|---|
| Heart functionCardiovascular | 541 | 7225515 |
|---|
| Immune responseImmune and inflammation | 11 | 861472 |
|---|
| PharmacokineticsPharmacology | 44 | 287183 |
|---|
| PainMusculoskeletal | 55 | 523 |
|---|
| Tumor growthCancer | 33 | 20119 |
|---|
| Kidney functionKidney and urinary | 22 | 14131 |
|---|
| Cardiovascular eventsCardiovascular | 55 | 11 |
|---|
| Exercise and physical functionMusculoskeletal | 44 | 11 |
|---|
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 21 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Radius Health, Inc.2,463 participantsApr 2011 to Oct 2014
Osteoporosis · Postmenopausal Osteoporosis
Radius Health, Inc.511 participants5 Aug 2019 to 9 Nov 2021
Postmenopausal Osteoporosis
Radius Health, Inc.228 participants3 May 2018 to 8 Sept 2021
Osteoporosis · Osteoporosis, Age-Related · Osteoporosis Localized to Spine · Age Related Osteoporosis · Osteoporosis Senile · Osteoporosis of Vertebrae
4 more mention it but do not test it. They only measure it or name it in their text.
Top 3 of 13 trials, ranked by phase, then posted results and enrollment: 2 completed · 1 stopped early · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
ReGenTree, LLC700 participants24 May 2019 to 7 Oct 2021
Dry Eye Syndromes · Dry Eye
ReGenTree, LLC601 participantsNov 2016 to Mar 2018
Dry Eye Syndrome
ReGenTree, LLC18 participants17 Sept 2015 to 9 Mar 2020
Neurotrophic Keratopathy
2 more mention it but do not test it. They only measure it or name it in their text.
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Abaloparatide (Tymlos) | Thymosin beta-4 (human) |
|---|---|---|
| Bone and jointMusculoskeletalCompared as: value in the arm that got the peptide, in % | 8.48% BMD percentage change Placebo: 1.17% Dose studied: 80 μg daily12 monthsn = 2282022 | No randomized trial result 53 results from other study designs. |
| Adverse eventsWhole bodyCompared as: value in the arm that got the peptide, in % | 3.6% Hypercalcemia · abaloparatide; eGFR <60 mL/min Dose studied: 80 µg daily18 monthsn not reported2019 | No comparable result 8 randomized-trial results measure it in another way or another unit. |
| Heart functionCardiovascularCompared as: value in the arm that got the peptide, in bpm | 7.9 bpm Heart rate change · abaloparatide at 1 hour Placebo at 1 hour: 1.2 bpm n not reported2020 | No comparable result 2 randomized-trial results measure it in another way or another unit. |
| Blood pressureCardiovascularCompared as: value in the arm that got the peptide, in mmhg | −2.7 mmHg Systolic pressure change n not reported2020 | No randomized trial result 2 results from other study designs. |
8.48%
BMD percentage change
Placebo: 1.17%
Dose studied: 80 μg daily12 monthsn = 2282022
No randomized trial result
53 results from other study designs.
3.6%
Hypercalcemia · abaloparatide; eGFR <60 mL/min
Dose studied: 80 µg daily18 monthsn not reported2019
No comparable result
8 randomized-trial results measure it in another way or another unit.
7.9 bpm
Heart rate change · abaloparatide at 1 hour
Placebo at 1 hour: 1.2 bpm
n not reported2020
No comparable result
2 randomized-trial results measure it in another way or another unit.
−2.7 mmHg
Systolic pressure change
n not reported2020
No randomized trial result
2 results from other study designs.